Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 8/20 | 0.59 |
| ▸ | CHRM3 | P20309 | 8/20 | 0.59 |
| ▸ | CHRM2 | P08172 | 7/20 | 0.59 |
| ▸ | CHRM4 | P08173 | 7/20 | 0.59 |
| ▸ | CHRM5 | P08912 | 6/20 | 0.59 |
| ▸ | CHRNB2 | P17787 | 4/20 | 0.59 |
| ▸ | CHRNA4 | P43681 | 4/20 | 0.59 |
| ▸ | CHRNA7 | P36544 | 3/20 | 0.59 |
| ▸ | HTR1A | P08908 | 2/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.59 |
| ▸ | LMNA | P02545 | 2/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.56 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.56 |
| ▸ | PGR | P06401 | 1/20 | 0.56 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.56 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.56 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.56 |
| ▸ | CHRNA10 | Q9GZZ6 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13033938 | 0.88 | CHRM1 (0.45) | CHRM1CHRM3CHRM2CHRM4CHRM5 | |
| SCHEMBL13033942 | 0.86 | CHRM1 (0.44) | CHRM1CHRM3CHRM2CHRM4CHRM5 | |
| SCHEMBL14742055 | 0.84 | CHRM1 (0.61) | CHRM1CHRM3CHRM2CHRM4CHRM5 | |
| SCHEMBL13033943 | 0.84 | CHRM5 (0.42) | CHRM1CHRM3CHRM2CHRM4CHRM5 | |
| SCHEMBL8221214 | 0.83 | CHRM1 (0.55) | CHRM1CHRM3CHRM2CHRM4CHRM5 | |
| SCHEMBL6001765 | 0.82 | CHRM1 (0.60) | CHRM1CHRM3CHRM2CHRM4CHRM5 | |
| SCHEMBL13785332 | 0.81 | CHRNB2 (0.41) | CHRNB2CHRNA4CYP2C19LMNATSHR | |
| Acetylcholine SCHEMBL22346031 | 0.80 | CHRM1 (0.70) | CHRM1CHRM3CHRM2CHRM4CHRM5 | |
| SCHEMBL3780770 | 0.80 | CHRM1 (0.58) | CHRM1CHRM3CHRM2CHRM4CHRM5 | |
| Hydrochloric Acid SCHEMBL28778365 | 0.80 | CHRM1 (0.61) | CHRM1CHRM3CHRM2CHRM4CHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107573401-A | The method that ion liquid solvent system dissolving fermentation bacteria residue prepares high polymer | 中国科学院过程工程研究所 | 2018-01-12 | — | — | CN | claimed |
| US-20100113334-A1 | METHODS FOR REDUCING OR PREVENTING TRANSMISSION OF NOSOCOMIAL PATHOGENS IN A HEALTH CARE FACILITY | LEACH TIMOTHY S | 2010-05-06 | — | — | US | claimed |
| US-20050043223-A1 | Methods for reducing or preventing transmission of nosocomial pathogens in a health care facility | OSCIENT PHARMACEUTICALS CORPORATION | 2005-02-24 | — | — | US | claimed |
| WO-2004096143-A2 | METHODS FOR REDUCING OR PREVENTING TRANSMISSION OF NOSOCOMIAL PATHOGENS IN A HEALTH CARE FACILITY | OSCIENT PHARMACEUTICALS CORPORATION (US) | 2004-11-11 | — | — | WO | claimed |
| US-20040147441-A1 | Methods and reagents for preventing bacteremias | OSCIENT PHARMACEUTICALS CORPORATION | 2004-07-29 | — | — | US | claimed |
| US-20040127403-A1 | Methods for treating and preventing Gram-positive bacteremias | OSCIENT PHARMACEUTICALS CORPORATION | 2004-07-01 | — | — | US | claimed |
| WO-2004017925-A2 | METHODS AND REAGENTS FOR PREVENTING BACTEREMIAS | GENOME THERAPEUTICS CORPORATION (US) | 2004-03-04 | — | — | WO | claimed |
| CN-107573401-B | Method for preparing high polymer by dissolving fermentation bacterium residues in ionic liquid solvent system | 中国科学院过程工程研究所 | 2021-07-13 | — | — | CN | disclosed |
| US-20190021998-A1 | TOPICAL NANOEMULSION THERAPY FOR WOUNDS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2019-01-24 | — | — | US | disclosed |
| US-9937234-B2 | Compositions and methods for using and identifying antimicrobial agents | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2018-04-10 | — | — | US | disclosed |
| CN-107573401-A | The method that ion liquid solvent system dissolving fermentation bacteria residue prepares high polymer | 中国科学院过程工程研究所 | 2018-01-12 | — | — | CN | disclosed |
| US-20170100335-A1 | TOPICAL NANOEMULSION THERAPY FOR WOUNDS | NANOBIO CORPORATION | 2017-04-13 | — | — | US | disclosed |
| US-20160271220-A1 | COMPOSITIONS AND METHODS FOR USING AND IDENTIFYING ANTIMICROBIAL AGENTS | UNIVERSITY OF VIRGINIA | 2016-09-22 | — | — | US | disclosed |
| US-20070060506-A1 | Compositions and methods for treating bacteria | BIOSYNEXUS INCORPORATED (US) | 2007-03-15 | — | — | US | disclosed |
| WO-2007014372-A2 | COMPOSITIONS AND METHODS FOR TREATING BACTERIA | BIOSYNEXUS INCORPORATED (US) | 2007-02-01 | — | — | WO | disclosed |
| US-20050043223-A1 | Methods for reducing or preventing transmission of nosocomial pathogens in a health care facility | OSCIENT PHARMACEUTICALS CORPORATION | 2005-02-24 | — | — | US | disclosed |
| WO-2004096143-A2 | METHODS FOR REDUCING OR PREVENTING TRANSMISSION OF NOSOCOMIAL PATHOGENS IN A HEALTH CARE FACILITY | OSCIENT PHARMACEUTICALS CORPORATION (US) | 2004-11-11 | — | — | WO | disclosed |
| US-20040147441-A1 | Methods and reagents for preventing bacteremias | OSCIENT PHARMACEUTICALS CORPORATION | 2004-07-29 | — | — | US | disclosed |
| US-20040127403-A1 | Methods for treating and preventing Gram-positive bacteremias | OSCIENT PHARMACEUTICALS CORPORATION | 2004-07-01 | — | — | US | disclosed |
| WO-2004017925-A2 | METHODS AND REAGENTS FOR PREVENTING BACTEREMIAS | GENOME THERAPEUTICS CORPORATION (US) | 2004-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190021998-A1 | TOPICAL NANOEMULSION THERAPY FOR WOUNDS | CUTA, MMP8, DSG1 | CHRM1 4068/4885CHRM3 3306/4885CHRM2 3131/4885 |
| US-20170100335-A1 | TOPICAL NANOEMULSION THERAPY FOR WOUNDS | CUTA, MMP8, DSG1 | CHRM1 4068/4885CHRM3 3306/4885CHRM2 3131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.